Hypertrichosis Lanuginosa Acquisita
Hypertrichosis lanuginosa acquisita (HLA), also known as malignant downy hair syndrome, is an extremely rare paraneoplastic skin syndrome, yet it is among the strongest and most direct cutaneous warning signs of internal cancer described in the medical literature. It is marked by the rapid, sudden growth of lanugo hair: fine, soft, unmedullated, unpigmented (white or pale yellow) hair of the kind normally seen only in the fetus, which is shed before birth.
Unlike hormonal hair growth (hirsutism) or congenital hypertrichosis, HLA is linked to an advanced, often hidden internal malignancy in more than 90% of cases. The most common underlying cancers include:
- Lung carcinoma: The most frequent association (about 40–50% of cases).
- Gastrointestinal cancers: Particularly colorectal, gastric, pancreatic and liver cancer (about 30–40%).
- Other tumors: Breast, ovarian and uterine cancer, and lymphoma.
At the molecular level, this abrupt change in the hair follicles happens because the tumor pours growth factors into the bloodstream, especially epidermal growth factor (EGF), TGF-alpha and hormone-like peptides that regulate the hair cycle. These signals push hair follicle stem cells out of the resting phase (telogen) and into continuous growth (anagen), while reversing the differentiation of mature follicles back to the fetal lanugo type.
At Haute-Derma, the appearance of HLA is treated as a medical emergency. Patients are immediately started on a full-body cancer screening pathway so that treatment can begin within the critical window.
Clinical Features and Paraneoplastic Symptoms
HLA has a very distinctive appearance and set of accompanying symptoms that make it hard to confuse with other forms of excess hair:
- Characteristics of the Hair Growth:
- Fine, velvety, white or pale yellow hair that grows unusually long (from 2 cm to more than 15 cm if left uncut).
- The hair appears abruptly, covering the face (cheeks, forehead, chin, ears) and neck, then quickly spreading over the trunk, forearms and lower legs. Only the palms, soles and mucous membranes are spared.
- Growth is so rapid that patients feel their facial appearance has completely changed within a few weeks.
- Associated Triad of Symptoms:
- Glossitis/glossodynia: A red, swollen, smooth tongue that burns when eating or drinking.
- Taste and smell disturbances (dysgeusia/anosmia): Loss of taste or a metallic taste in the mouth.
- Severe weight loss: Together with loss of appetite and fatigue from cancer cachexia.
HLA vs. Hirsutism vs. Drug-Induced Hypertrichosis
| Hypertrichosis Lanuginosa Acquisita (HLA) | Hirsutism (Hormonal) | Drug-Induced Hypertrichosis |
|---|---|---|
| Paraneoplastic syndrome of malignancy (lung, colon, stomach) | Excess androgens (polycystic ovary syndrome, adrenal tumors) | Side effect of medication (cyclosporine, minoxidil, phenytoin) |
| Fine, soft, unpigmented lanugo hair (white/yellow) | Thick, coarse, dark terminal hair (black/brown) | Vellus or terminal hair, mildly darker |
| Whole body, especially the entire face and ears | Androgen-sensitive areas (upper lip, chin, chest, linea alba) | Usually extensor limbs, forehead, back |
| Very rapid onset (weeks) | Develops slowly over months or years | Appears weeks to months after starting the drug |
| Marked weight loss, glossitis, loss of taste, internal tumor | Acne, androgenetic hair loss, menstrual irregularities | No wasting or internal malignancy |
| >90% cancer | <1% (unless an androgen-secreting adrenal or ovarian tumor) | 0% |
Diagnosis and Clinical Management at Haute-Derma
For patients who suddenly develop HLA, Haute-Derma follows an urgent management pathway:
Dermoscopy and Ruling Out External Causes
- Digital dermoscopy: Shows fine hairs without a medulla and a sharply increased density of anagen follicles per unit area, with no red inflammatory papules or perifollicular pigmentation.
- Thorough medication history: Rules out drugs that cause excess hair, such as minoxidil (oral or topical), cyclosporine, phenytoin, glucocorticoids or diazoxide.
No Early Cosmetic Hair Removal
- No laser hair removal or widespread waxing: Diode laser or IPL hair removal, waxing, shaving or chemical depilation should not be rushed into before the underlying cause is found. Hair removal cannot stop new hair from growing while the tumor keeps releasing growth factors into the blood; it also irritates the skin and delays cancer screening.
- Supportive care: If facial hair is causing significant distress while screening is underway, it can be gently trimmed with sterile cosmetic scissors or a personal dry shaver, along with a barrier-repair cream.
Full-Body Cancer Screening
A case file is opened immediately and the patient is urgently referred to a national-level oncology center for the following work-up:
- Lung cancer screening: High-resolution CT of the chest (HRCT thorax) and lung tumor markers (CYFRA 21-1, NSE, CEA).
- Gastrointestinal cancer screening: Flexible upper endoscopy and colonoscopy with chromoendoscopy, multislice abdominal CT (to look for pancreatic and liver tumors), and CEA and CA 19-9 levels.
- Gynecologic and breast cancer screening (women): Pelvic ultrasound, mammography, and CA 125 and CA 15-3 levels.
- Whole-body PET-CT: Prioritized when standard tests have not located the primary tumor.
